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Introduction: Several guidelines recommend initial empirical treatment with two antibiotics instead of one to
decrease mortality in community-acquired pneumonia (CAP) requiring intensive-care-unit (ICU) admission. We
compared the impact on 60-day mortality of using one or two antibiotics. We also compared the rates of nosocomial
pneumonia and multidrug-resistant bacteria.
Methods: This is an observational cohort study of 956 immunocompetent patients with CAP admitted to ICUs in
France and entered into a prospective database between 1997 and 2010.
Patients with chronic obstructive pulmonary disease were excluded. Multivariate analysis adjusted for disease
severity, gender, and co-morbidities was used to compare the impact on 60-day mortality of receiving adequate
initial antibiotics and of receiving one versus two initial antibiotics.
Results: Initial adequate antibiotic therapy was significantly associated with better survival (subdistribution hazard
ratio (sHR), 0.63; 95% confidence interval (95% CI), 0.42 to 0.94; P = 0.02); this effect was strongest in patients with
Streptococcus pneumonia CAP (sHR, 0.05; 95% CI, 0.005 to 0.46; p = 0.001) or septic shock (sHR: 0.62; 95% CI 0.38 to
1.00; p = 0.05). Dual therapy was associated with a higher frequency of initial adequate antibiotic therapy. However,
no difference in 60-day mortality was found between monotherapy (β-lactam) and either of the two dual-therapy
groups (β-lactam plus macrolide or fluoroquinolone). The rates of nosocomial pneumonia and multidrug-resistant
bacteria were not significantly different across these three groups.
Conclusions: Initial adequate antibiotic therapy markedly decreased 60-day mortality. Dual therapy improved the
likelihood of initial adequate therapy but did not predict decreased 60-day mortality. Dual therapy did not increase
the risk of nosocomial pneumonia or multidrug-resistant bacteria.Introduction
Community-acquired pneumonia (CAP) is among the
most common severe infections in critically ill patients [1]
and is associated with a high death toll. Failure to use ad-
equate antibiotics (that is, antibiotics active in vitro on the
causative organism) considerably increases the risk of
death, particularly in patients with severe sepsis [2,3].
Consequently, the recommended antibiotic regimen for* Correspondence: christophe.adrie@outcomerea.org
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reproduction in any medium, provided the orpatients with CAP requiring hospital admission is either a
fluoroquinolone alone or a combination of two antibiotics,
including a macrolide [4-6]. Many trials suggest greater
efficacy of dual therapy (usually with a β-lactam and a
macrolide or fluoroquinolone) compared to monotherapy
(usually with a β-lactam) [3,7-15]. Macrolides may be par-
ticularly useful, as they blunt the inflammatory response
via immunomodulating effects and may exert effects on
bacteria not included in their spectrum [16]. However,
current recommendations are based chiefly on theoretical
grounds, as opposed to high-quality studies [17-19]. Fur-
thermore, a systematic review of randomized controlledtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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covering atypical pathogens improved survival or clinical
efficacy in patients admitted for CAP [18].
Our primary objective in this observational cohort study
of a prospective database was to determine whether using
two initial antibiotics instead of one improved 60-day
mortality in patients admitted to the ICU for CAP. We
also assessed the effect on 60-day mortality of receiving
adequate antibiotic therapy initially versus secondarily.
Subgroup analyses were done in patients with specific or-
ganisms and in those with the most severe acute-illness
syndromes. The risks of nosocomial pneumonia and
multidrug-resistant (MDR) bacteria were compared in pa-
tients given one versus two antibiotics.
Material and methods
Inclusion and exclusion criteria
Because diagnostic coding using the International Classifi-
cation of Diseases has been found unreliable in the ICU
[20], we used parameters collected prospectively by data-
capture software to identify the 956 patients admitted to
12 ICUs for CAP between 1996 and 2010 and included in
the OutcomeRea® database (www.outcomerea.org). Patients
were classified into three groups based on antibiotics re-
ceived for at least 48 hours within the first three days after
ICU admission: β-lactam alone, β-lactam plus macrolide
and β-lactam plus fluoroquinolone.
We excluded patients given non-β-lactam monother-
apy; patients with chronic obstructive pulmonary disease
(COPD), pneumonia more than two days after ICU ad-
mission (possible ICU-acquired pneumonia), previous
hospitalization, or immunodeficiency (or example, HIV
infection, long-term glucocorticoid therapy, long-term
hemodialysis, or cancer chemotherapy); [21] and patients
who died within three days after ICU admission.
Definitions
CAP was defined as symptoms and signs consistent with
lower respiratory tract infection, new lung infiltrates by
radiography or computed tomography, and infection ac-
quired outside the hospital [4]. Patients with CAP were
identified based on the ICU-admission diagnosis and
microbiological findings in blood and respiratory tract
specimens (sputum, bronchoalveolar lavage fluid, endo-
tracheal aspirates or protected plugged catheter) [22],
according to recently updated definitions developed by
the Centers for Disease Control and the International
Sepsis Consensus Conference [23]. We also took into ac-
count the results of urinary antigen tests for Legionella
pneumophila (serotype 1) and Streptococcus pneumoniae.
Initial adequate antibiotic therapy was defined as one
or more antibiotics active in vitro on the identified mi-
croorganisms or, in non-documented CAP, as treatment
according to current guidelines [5], started at ICUadmission and not requiring a change (secondary adjust-
ment of antibiotic therapy) upon re-evaluation 48 hours
later. Classical definitions were used for sepsis, severe
sepsis and septic shock [24]. MDR bacteria were divided
into four classes (methicillin-resistant Staphylococcus aureus
(MRSA); extended-spectrum β-lactamase (ESBL)-producing
Enterobacteriacae; non-fermenting bacteria (Pseudomonas
species, Acinetobacter spp., and Stenotrophomonas maltophi-
lia); and Clostridium difficile). Treatment duration was at
least five days [5] but was otherwise at the discretion of
the attending physician.
Data collection
Data were collected daily by senior physicians in the partici-
pating ICUs. For each patient, the data were entered into an
electronic case-report form using VIGIREA® and RHEA®
data-capture software, and all case-report forms were then
entered into the OutcomeRea® data warehouse (Outcomeréa,
Paris, France). All codes and definitions were established
prior to study initiation. For each patient, age, sex and
McCabe score were recorded. Severity of illness was evalu-
ated on the first ICU day using the Simplified Acute Physi-
ology Score (SAPS II), Sequential Organ Failure Assessment
(SOFA) score and Glasgow Coma Scale (GCS) score. Knaus
scale definitions [25] were used to record pre-existing
chronic organ failures, including respiratory, cardiac, hepatic,
renal and immune system failures. Finally, the CURB-65
(Confusion, Urea, Respiratory rate, Blood pressure in ≥65-
year-old patients) severity score was determined [26].
Variables
Relationships with mortality and other endpoints were
evaluated for the following variables: severity scores; age;
sex; ICU and hospital stay lengths; co-morbidities; presence
at admission of sepsis, severe sepsis or septic shock; use of
invasive or noninvasive ventilation, inotropic agents, gluco-
corticoids or hemodialysis-hemofiltration; and recovered
pathogens.
Quality of the database
The data-capture software automatically conducted mul-
tiple checks for internal consistency of most of the vari-
ables at entry into the database. Queries generated by
these checks were resolved with the source ICU before
incorporation of the new data into the database. At each
participating ICU, data quality was controlled by having
a senior physician from another participating ICU check
a 2% random sample of the study data. A one-day cod-
ing course was held annually for the study investigators
and contract research organization monitors.
Ethical issues
This study was approved by our institutional review board
(CECIC Clermont-Ferrand - IRB n°5891; Ref: 2007-16),
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the participants, in accordance with French legislation
on non-interventional studies. However, the patients
and their next of kin were asked whether they were will-
ing to participate in the database, and none declined
participation.
Statistical analyses
The data are described as the number (%) for categorical
variables and median (interquartile range) for continu-
ous variables, unless stated otherwise. Comparisons re-
lied on the Fisher exact test or χ2 test for categorical
data and on the Kruskal-Wallis test for continuous data.
The primary outcome was 60-day mortality and the sec-
ondary outcomes were first episodes of nosocomial pneu-
monia with and without MDR bacteria. Patient outcomes
were censored 60 days after ICU admission. Because pa-
tients discharged alive from the hospital within the first
60 days represented an informative censor for assessing
mortality, nosocomial infection and presence of MDR
bacteria, a Fine-and-Gray adaptation of the Cox model
was used. Results were expressed as sub-distribution
hazard ratios (sHR) with their 95% confidence intervals
(95% CIs).
Variables yielding P-values <0.20 by univariate analysis
were entered into a multivariate model using backward
selection, with P <0.05 considered significant. Gluco-
corticoid therapy and time to initial therapy were forced
into the model. The following variables collected at ICU
admission were considered for the multivariate model:
gender, SAPSII, co-morbidities, severe sepsis, septic
shock, invasive mechanical ventilation, glucocorticoid
therapy, time to initial antibiotic therapy, hemodialysis-
hemofiltration, bacteremia and pathogens with P <0.20
by univariate analysis. Among severity markers, the SAP-
SII was selected, because it had a better Akaike Informa-
tion Criterion compared to CURB-65, or SOFA score
and age. Continuous variables were proposed to the
model in their native form if they verified the log-
linearity assumption; otherwise, they were converted and
entered as dummy variables. Clinically sound two-way
interactions were tested. Sub-analyses were performed
considering only patients with identified pathogens
or with septic shock. Adjusted sHR values with their
95% CIs were calculated for each parameter estimate.
P-values <0.05 were considered significant. Analyses
were performed using the SAS 9.2 software package
(SAS Institute, Cary, NC, USA).
Results
Patients
Of the 13,200 patients entered into the database in 1997
to 2010, 956 met our selection criteria (see flow chart in
Figure 1). Table 1 lists their main characteristics. Crude60-day mortality was 259 (27.1%). Interestingly, the pro-
portion of patients with S. pneumoniae was only 21%,
but as many as 11% of patients had S. aureus, and
Gram-negative bacilli were common. Of note, Entero-
bacteriaceae (all species) and Pseudomonas aeruginosa
were found in 9% and 3% of patients, respectively.
As expected, survivors and non-survivors differed sig-
nificantly regarding multiple organ failure prevalence,
co-morbidities, gender and CURB-65 score. Compared
to survivors, non-survivors had higher rates of P. aerugi-
nosa, Escherichia coli, K. pneumonia, P. mirabilis and
bacteremia (Table 1). However, none of these character-
istics was independently associated with mortality in the
multivariate analysis adjusted for confounders (SAPSII,
at least one co-morbidity and gender). Nosocomial
pneumonia after the CAP episode was associated with
higher mortality in the unadjusted analysis but not in
the adjusted analysis.
Impact of initial adequate antibiotic therapy on 60-day
mortality
Initial adequate antibiotic therapy was independently as-
sociated with better survival in the overall cohort (sHR,
0.63; 95% CI, 0.42 to 0.94.00; P = 0.02) (Table 2). Survival
in patients who received initial inadequate therapy was
not improved by secondary adjustment of the antibiotic
regimen. Initial dual therapy was significantly associated
with initial adequate therapy (P = 0.0007). There was a
trend toward better survival with initial adequate anti-
biotic therapy in the subgroup with septic shock (sHR,
0.59; 95% CI, 0.32 to 1.08; P = 0.09) but not in the sub-
groups with sepsis or severe sepsis.
Impact of one vs. two initial antibiotics on 60-day
mortality
A β-lactam was used alone in 471 patients and in combin-
ation with another antibiotic in 394 patients, including
164 given a macrolide and 230 given a fluoroquinolone
(Figure 1 and Table 3). The main clinical characteristics of
these two groups are listed in Table 3. The fluoroquino-
lones were ciprofloxaxin in 56 (24%) patients, levofloxacin
in 42 (18%), ofloxacin in 41 and unspecified in 38 (17%).
The shorter duration of antibiotic therapy in the mono-
therapy group may be related to the higher rate of patho-
gen identification compared to the dual-therapy group.
Among patients given dual therapy, those treated with
fluoroquinolones had greater disease severity and a higher
crude 60-day mortality rate than those given macrolides.
By multivariate analysis, 60-day mortality was not sig-
nificantly different between dual therapy and monother-
apy (sHR, 1.14; 95% CI, 0.86 to 1.50; P = 0.37), even
when the analysis was restricted to patients with S.
pneumonia, those with documented infection, or those
with septic shock (Table 4). By multivariate analysis,
Patients, n=13 200 
Included Patients with CAP atadmission, 
n=956




Patients with CAP atadmission, n=1493
COPD, Corticosteroids>1month or  
>2mg/Kg,cancers, AIDS n=537
Treatment without beta-lactam, n=91  
Crude hospital mortality:        74  32.2%)
Non-documentedpathogens: 130 (56.2%)
Severe sepsis:                        214 (93.0%)
Septic shock:                          97 (42.2%)
Bacteremia:                            27 (11.7%)
Crude hospital mortality:         39 (23.8%)
Non-documented pathogens:  77 (47.0%)
Severe sepsis:                         146 (89.0%)
Septic shock:                            55 (33.5%)
Bacteremia:                              15 (9.2%)
Crude Hospital mortality:             131 (27.8%)
Non-documented pathogens:      182 (38.6%)
Severe sepsis:                             395 (83.9%)
Septic shock:                               146 (31.0%)
Bacteremia:                                  74  (15.7%)
Figure 1 Flow diagram of the patients with community-acquired pneumonia (CAP).
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the macrolide and fluoroquinolone subgroups (sHR, 1.45;
95% CI, 0.78 to 2.70; P = 0.24), even when the analysis was
restricted to patients with S. pneumonia, those with docu-
mented infection, or those with septic shock. These results
were unchanged when the analysis was confined to pa-
tients given initial adequate antibiotic therapy.
The following variables at admission were considered
for entry into the model: gender, SAPSII, at least one co-
morbidity, severe sepsis, septic shock, invasive ventila-
tion, steroid therapy, day of antibiotic therapy initiation,
steroids, hemodialysis-hemofiltration, bacteremia and
pathogens yielding P-values <0.2 by univariate analysis.
Impact of one vs. two antibiotics on nosocomial
pneumonia and multidrug-resistant bacteria rates
Nosocomial pneumonia developed in 127 patients, and
MDR bacteria were identified in 105 patients. Neither the
rate of nosocomial pneumonia nor the rate of MDR bacteria
recovery differed significantly across the three antibiotic
treatment groups (monotherapy, dual therapy with a macro-
lide and dual therapy with a fluoroquinolone; Table 3).
Discussion
In a very large cohort of immunocompetent ICU patients
with CAP, initial adequate antibiotic therapy improved60-day survival and the improvement was greatest in the
patients with S. pneumoniae infection or septic shock. Ini-
tial dual antibiotic therapy (β-lactam plus macrolide or
fluoroquinolone) was associated with a higher frequency of
adequate initial therapy but was not associated with better
60-day survival compared to β-lactam monotherapy. Dual
therapy did not significantly affect the risk of nosocomial
pneumonia or MDR bacteria compared to monotherapy.
Our study provides a good picture of the pathogens
responsible for CAP requiring ICU admission. The dis-
tribution of the pathogens was consistent with previ-
ously published results, which vary widely, however,
perhaps in relation to variations in case-mix [6]. Thus,
the prevalence of S. pneumoniae infection in our study
was only about half that found in a vast cohort of 3,523
patients in Spain [27], whereas the prevalence of Gram-
negative bacilli was similar. The Spanish study included
15% of outpatients and 85% of inpatients admitted to
wards or ICUs, whereas we studied only ICU patients, a
population possibly characterized by greater bacterial
virulence, greater bacterial resistance, and/or a longer
time to treatment. Despite our restrictive inclusion cri-
teria, Enterobacteriaceae and Pseudomonas aeruginosa
were identified in 9.2% and 3% of patients, respectively.
These pathogens, which raise specific treatment challenges,
are typically found in healthcare-associated pneumonia
Table 1 Patient characteristics and pathogens
Parameters Total (n = 956) Died within 60 days
(n = 259, 27%)*
Alive on day 60
(n = 697, 73%)
P-value
Variables at admission
Male, n (%) 633 (66.2) 190 (73.4) 443 (63.6) 0.004
Age, years (median [IQR]) 62 [46; 76] 72 [58; 80] 58 [42; 73] <0.0001
Scores, median [IQR]
SAPSII 43.5 [31; 59] 60 [43; 74] 39 [27; 53] <0.0001
SOFA score 6 [4; 9] 9 [6; 12] 5 [3; 8] <0.0001
LOD score 5 [2; 7] 7 [4; 10] 4 [2; 6] <0.0001
Coma Glasgow Scale 13 [5; 15] 7 [3; 15] 14 [7; 15] <0.0001
McCabe, n (%) <0.0001
1 684 (71.7) 140 (54.1) 544 (78.3)
2 235 (24.6) 98 (37.8) 137 (19.7)
3 35 (3.7) 21 (8.1) 14 (2.0)
CURB-65, n (%) <0.0001
0 13 (1.4) 0 (0) 13 (1.9)
1 62 (6.5) 4(1.6) 58 (8.3)
2 176 (18.4) 22 (8.5) 154 (22.1)
3 292 (30.6) 65 (25.2) 227 (32.6)
4 252 (26.4) 90 (34.9) 162 (23.2)
5 160 (16.8) 77 (29.8) 83 (11.9)
Co-morbidities (Knaus definitions), n (%)
Chronic hepatic failure 43 (4.5) 22 (8.5) 21 (3.0) 0.0003
Chronic heart failure 107 (11.2) 38 (14.7) 69 (9.9) 0.04
Chronic respiratory failure 167 (17.5) 55 (21.2) 112 (16.1) 0.06
Chronic renal failure 19 (2.0) 7 (2.7) 12 (1.7) 0.33
Diabetes 123 (12.9) 40 (15.4) 83 (11.9) 0.15
≥ One co-morbidity 352 (36.8) 124 (47.9) 228 (32.7) <0.0001
Smokers ( >20 pack-year), n (%) 243 (30.6) 57 (26.6) 186 (32.1) 0.14
Alcohol ( >80 g/day), n (%) 189 (23.8) 44 (20.6) 145 (25.0) 0.19
Sepsis, n (%) 928 (97.1) 252(97.3) 676 (97.0) 0.80
Severe sepsis, n (%) 828 (86.6) 235 (90.7) 593 (85.1) 0.02
Septic shock, n (%) 325 (34.0) 132 (51.0) 193 (27.7) <0.0001
Treatments, n (%) unless otherwise stated
Invasive ventilation 604 (63.3) 207 (79.9) 397 (57.0) <0.0001
Noninvasive ventilation 107 (11.2) 25 (9.7) 82 (11.8) 0.36
Inotropes or vasoactive agents 422 (44.1) 167 (64.5) 255 (36.6) <0.0001
Corticosteroids 182 (19.0) 66 (25.5) 116 (16.6) 0.002
Hemodialysis/hemofiltration 63 (6.6) 33 (12.7) 30 (4.3) <0.0001
Antibiotic therapy duration in days (median [IQR]) 7 [4; 13] 8 [3; 15] 7 [4; 13] 0.69
Organisms, n (%)
Streptococcus pneumoniae 202 (21.1) 52 (20.1) 150 (21.5) 0.63
Staphylococcus aureus 104 (10.9) 31(12.0) 73 (10.5) 0.51
Streptococcus spp. 36 (3.8) 12 (4.6) 24 (3.4) 0.39
Enterocococcus spp. 3 (0.3) 0 3 (0.4) 0.29
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Table 1 Patient characteristics and pathogens (Continued)
Hemophilus influenzae 97 (10.1) 25 (9.7) 72 (10.3) 0.76
Escherichia coli 34 (3.6) 16 (6.2) 18 (2.6) 0.008
Enterobacter spp. 13 (1.4) 6 (2.3) 7 (1.0) 0.12
Klebsiella pneumoniae 28 (2.9) 13 (5.0) 15 (2.2) 0.02
Serratia marescens 4 (0.4) 0 (0) 4 (0.6) 0.22
Proteus mirabilis 9 (0.9) 5 (1.9) 4 (0.6) 0.05
Pseudomonas aeruginosa 29 (3.0) 16 (6.2) 13 (1.9) 0.0005
Legionella pneumophila 25 (2.6) 4 (1.5) 21 (3.0) 0.21
Mycoplasma pneumoniae 1 (0.1) 0 (0) 1 (0.1) 0.54
Chlamydia pneumoniae 2 (0.2) 1 (0.4) 1 (0.1) 0.47
Aspergillus fugimatus 3 (0.3) 2 (0.8) 1 (0.1) 0.12
Mycobacterium tuberculosis 14 (1.5) 3 (1.2) 11 (1.6) 0.63
Viruses 24 (2.5) 3 (1.2) 21 (3.0) 0.10
Other 14 (1.5) 4 (1.5) 10 (1.4) 0.90
Multiple organisms 92 (9.6) 29 (11.2) 63 (9.0) 0.31
None identified 418 (43.7) 99 (38.2) 319 (45.8) 0.04
Bacteremia 121 (12.7) 45 (17.4) 76 (10.9) 0.008
Acquisition of MDR pathogen or nosocomial pneumonia, n (%)
MDR bacteria 105 (11.0) 34 (13.1) 71(10.2) 0.19
MRSA 25 (2.6) 9 (3.5) 16 (2.3) 0.31
Enterobacteriaceae ESBL 38 (4.0) 15 (5.8) 23 (3.3) 0.08
Nonfermentative GNB 56 (5.9) 16 (6.2) 40 (5.7) 0.80
Clostridium difficile 9 (0.9) 2 (0.8) 7 (1.0) 0.74
Nosocomial pneumonia 127 (13.3) 48 (18.5) 79 (11.3) 0.004
ICU stay in days, median [IQR] 7 [3; 15] 8 [3; 17] 6 [3; 14] 0.45
Hospital stay in days, median [IQR] 16 [8; 31] 10 [4; 22] 18 [10; 38] <0.0001
*273 (28.6) patients died in all, including 259 (27.1%) within 60 days and 54 (5.6%) within 48 h of ICU admission.
ESBL, extended-spectrum beta-lactamase; GNB, Gram-negative bacilli, Nonfermentative GNB (Pseudomonas spp., Acinetobacter baumannii, Stenotrophomonas
maltophilia); IQR, interquartile range; LOD, Logistic Organ Dysfunction Score; MDR, multidrug resistant; MRSA, methicillin-resistant Staphylococcus aureus.
Table 2 Factors independently associated with 60-day mortality between initially and secondarily adequate antibiotic
therapy groups
Multivariate analysis (n = 898) sHR (95% CI) P-value
Inadequate antibiotic therapy (reference) 0.63 (0.42 to 0.94) 0.02
Initial adequate antibiotic therapy
Secondary adequate antibiotic therapy 0.69 (0.37 to 1.27) 0.23
SAPSII per 10 points 1.65 (1.53 to 1.77) <.0001
Female gender 0.70 (0.52 to 0.94) 0.02
At least one co-morbidity 1.49 (1.13 to 1.97) 0.005
Adequate antibiotic therapy on day 2 versus day 1 1.33 (0.92 to 1.93) 0.13
Adequate antibiotic therapy on day 3 versus day 1 1.29 (0.76 to 2.20) 0.35
Corticosteroids 0.98 (0.72 to 1.32) 0.87
95% CI, 95% confidence interval; SAPSII, Simplified Acute Physiology Score version II; sHR, subdistribution hazard ratio.
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Male, n (%) 301 (63.9) 274 (69.5) 110 (67.1) 164 (71.3)
Age in years, median [IQR] 60 [45; 75] 64 [48; 77] 64 [49; 79] 64 [47; 76]
Scores, n (%)
SAPSII*£ 47 [34; 60] 39.5 [28; 57] 37 [28.5; 51] 43[28; 63]
SOFA score£ 6 [4; 9] 6 [3; 9] 5 [3; 8] 7 [4; 10]
LOD score*£ 5 [3; 7] 4 [2; 7] 3 [2; 5.5] 4 [2; 8]
Coma Glasgow Scale*£ 8 [4; 15] 15 [8.5; 15] 15 [11;15] 14 [7; 15]
McCabe, n (%)
1 326 (69.2) 284 (72.4) 119 (73.5) 165 (71.7)
2 124 (26.3) 98 (25.0) 40 (24.7) 58 (25.2)
3 21 (4.5) 10 (2.6) 3 (1.9) 7 (3.0)
CURB-65,* n (%)
0 3 (0.6) 7 (1.8) 1 (0.6) 6 (2.6)
1 20 (4.2) 38 (9.6) 15 (9.1) 23 (10.0)
2 88 (18.7) 71 (18.0) 34 (20.7) 37 (16.1)
3 157 (33.3) 107 (27.2) 42 (25.6) 65 (28.3)
4 122 (25.9) 107 (27.2) 46 (28.0) 61 (26.5)
5 81 (17.2) 64 (16.2) 26 (15.9) 38 (16.5)
Co-morbidities (Knaus definitions), n (%)
Chronic hepatic failure£ 23 (4.9) 17 (4.3) 3 (1.8) 14 (6.1)
Chronic heart failure 47 (10.0) 48 (12.2) 25 (15.2) 23 (10.0)
Chronic respiratory failure*£ 65 (13.8) 86 (21.8) 52 (31.7) 34 (14.8)
Chronic renal failure 9 (1.9) 7 (1.8) 3 (1.8) 4 (1.7)
Diabetes 58 (12.3) 48 (12.2) 16 (9.8) 32 (13.9)
≥One co-morbidity* 153 (32.5) 161 (40.9) 75 (45.7) 86 (37.4)
Smokers (>20 pack-years), n (%) 114 (31.1) 97 (28.1) 41 (29.3) 56 (27.3)
Alcohol (>80 g/d)* n (%) 101 (27.6) 73 (21.2) 31 (22.1) 42 (20.5)
Sepsis, n (%) 458 (97.2) 383 (97.2) 158 (96.3) 225 (97.8)
Severe sepsis, n (%) * 395 (83.9) 360 (91.4) 146 (89) 214 (93.0)
Septic shock, n (%)* 146 (31.0) 152(38.6) 55 (33.5) 97(42.2)
Treatments, n (%) unless otherwise stated
Invasive ventilation*£ 340 (72.2) 207 (52.5) 73 (44.5 134 (58.3)
Noninvasive ventilation* 40 (8.5) 58 (14.7) 27 (16.5) 31 (13.5)
Inotropes or vasoactive agents*£ 189 (40.1) 191 (48.5) 67 (40.9) 124 (53.9)
Corticosteroids* 69 (14.6) 96 (24.4) 40 (24.4) 56 (24.3)
Hemodialysis/Hemofil-tration 23 (4.9) 31 (7.9) 11 (637) 20 (8.7)
Antibiotic therapy duration in days, median [IQR]* 7 [4; 13] 8 [4; 14] 7 [4; 13] 8 [4; 15]
Organisms, n (%)
Streptococcus pneumoniae*£ 125 (26.5) 69 (17.5) 42 (25.6) 27 (11.7)
Staphylococcus aureus*£ 65 (13.8) 25 (6.3) 5 (3.0) 20 (8.7)
Streptococcus spp. 22 (4.7) 9 (2.3) 2 (1.2) 7 (3.0)
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Table 3 Comparison of the groups given monotherapy and dual therapy (Continued)
Enterocococcus spp. 3 (0.6) 0 (0) 0 (0) 0 (0)
Hemophilus influenzae* 57 (12.1) 29 (7.4) 15 (9.1) 14 (6.1)
Klebsiella pneumoniae 16 (3.4) 8 (2.0) 3 (1.8) 5 (2.2)
Escherichia coli 23 (4.9) 10 (2.5) 2 (1.2) 8 (3.5)
Enterobacteriaceae spp.* 11 (2.3) 2 (0.5) 1 (0.6) 1 (0.4)
Serratia marescens 3 (0.6) 1 (0.3) 0 (0) 1 (0.4)
Proteus mirabilis 7 (1.5) 1 (0.3) 0 (0) 1 (0.4)
Pseudomonas aeruginosa 13 (2.8) 14 (3.6) 5 (3.0) 9 (3.9)
Legionella pneumophila* 1 (0.2) 9 (2.3) 5 (3.0) 4 (1.7)
Mycoplasma pneumoniae 0 (0) 0 (0) 0 (0) 0 (0)
Chlamydia pneumoniae 0 (0)) 2 (0.5) 0 (0) 2 (0.9)
Mycobacterium tuberculosis£ 3 (0.6) 6 (1.5) 5 (3.0) 1 (0.4)
Aspergillus fumigatus 0 (0) 3 (0.8) 2 (1.2) 1 (0.4)
Viruses* 6 (1.3) 15 (3.8) 7 (4.3) 8 (3.5)
Other 6 (1.3) 6 (1.5) 1 (06) 5 (2.2)
Multiple organisms* 62 (13.2) 22 (5.6) 8 (4.9) 14 (6.1)
None identified* 182 (38.6) 207 (52.5) 77 (47.0) 130 (56.5)
Bacteremia* 74 (15.7) 42 (10.7) 15 (9.1) 27 (11.7)
Acquisition of MDR pathogens or nosocomial pneumonia, n (%)
MDR bacteria 52 (11.0) 44 (11.2) 19 (11.6) 25 (10.9)
MRSA 12 (2.5) 12 (3.0) 5 (3.0) 7 (3)
Enterobacteriaceae ESBL 22 (4.7) 12 (3.0) 5 (3.0) 7 (3)
Nonfermentative GNB 25 (5.3) 25 (6.3) 14 (8.5) 11 (4.8)
Clostridium difficile 6 (1.3) 2 (0.5) 0 (0) 2 (0.9)
Nosocomial pneumonia 58 (12.3) 54 (13.7) 23 (14) 31 (13.5)
ICU stay in days, median [IQR] 6 [3; 15] 7 [3; 16] 7 [3.5; 15.5] 8 [3; 17]
Hospital stay in days, median [IQR] 15 [8; 33] 18 [10; 31] 17.5 [10.5; 35] 18 [9; 30]
Patients who died within 60 days,£ n (%) 123 (26.1) 107 (27.2) 35 (21.3) 72 (31.3)
ESBL, extended-spectrum beta-lactamase; LOD, Logistic Organ Dysfunction Score; MDR, multidrug resistant; MRSA, methicillin-resistant Staphylococcus aureus;
Nonfermentative GNB, nonfermentative Gram-negative bacilli (Pseudomonas spp., Acinetobacter baumannii, Stenotrophomonas maltophilia).
*P <0.05 for monotherapy (n = 471) versus dual therapy (n = 394); £P <0.05 for β-lactam +macrolide (n = 164) vs. β-lactam + fluoroquinolone (n = 230).
Table 4 Factors associated with 60-day mortality in the groups given monotherapy or dual therapy
Multivariate analysis sHR 95% CI P-value
Dual therapy versus monotherapy 1.14 0.86 to 1.50 0.37
SAPSII (per 10 points) 1.66 1.54 to 1.79 <.0001
Female gender 0.72 0.53 to 0.96 0.03
≥One co-morbidity 1.43 1.07 to 1.91 0.01
Antibiotic therapy on Day 2 versus Day 1 1.38 0.98 to 1.93 0.07
Antibiotic therapy on Day 3 versus Day 1 1.28 0.75 to 2.19 0.36
Steroids 0.97 0.71 to 1.32 0.83
Multivariate sensitivity analysis* sHR (95% CI) P-value
Restricted to Streptococcus pneumoniae infection 1.42 0.73 to 2.77 0.31
Restricted to documented infection 1.29 0.89 to 1.89 0.18
Restricted to patients with septic shock 1.11 0.75 to 1.64 0.59
*Adjusted on SAPSII, female gender, at least one co-morbidity, day of antibiotic therapy initiation and use of steroids.
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to acute illness severity, acute organ dysfunction, the pres-
ence of at least one co-morbidity and gender [29], but not
to the nature of the pathogens, confirming our previous
findings [30].
The better 60-day survival associated with initial ad-
equate antibiotic therapy, particularly in the patients
with the greatest disease severity, is consistent with
many studies documenting the importance of very early
adequate antibiotic administration in septic shock and
severe pneumonia [2,31,32]. Dual therapy significantly
increased the frequency of initial adequate therapy but
did not increase survival. This apparent inconsistency in
our findings may be ascribable to the fact that adequate
therapy in patients without bacteriological documentation
was defined in our study as compliance with guidelines.
Another possible explanation is insufficient statistical
power, although our cohort was large. So the effect of dual
therapy in improving initial treatment adequacy may
have been too small to induce a significant decrease in
mortality.
Our finding that 60-day mortality was not significantly
decreased by using two initial antibiotics instead of one,
even in patients with septic shock or S. pneumoniae infec-
tion, may appear to contradict earlier studies [3,8,9,21].
These discrepancies may be ascribable to differences in
disease severity, causative organisms, antibiotics used, ex-
clusion criteria and primary outcome measures. Thus, a
prospective observational study of ICU patients found that
dual therapy improved survival in the subgroup with
shock, whereas no difference with monotherapy was
noted in the subgroup without shock; however, survival
was recorded at ICU discharge or on Day 28 [3]. In an-
other prospective observational ICU study, in which
75.7% of the patients had shock; dual therapy, including a
macrolide, was associated with better ICU survival com-
pared to dual therapy with a fluoroquinolone [8], whereas
we found no significant difference in 60-day mortality be-
tween these two groups. Although one of these studies ex-
cluded patients with COPD [3] and the other excluded
patients with immunodeficiencies [8], neither used all the
exclusion criteria used in our study. Two other studies fo-
cused on S. pneumoniae disease. One was a prospective
observational study of patients with S. pneumoniae
bacteremia showing that dual therapy improved 14-day
survival in the subgroup requiring ICU admission but not
in the subgroup managed on the wards [9]. In patients
with S. pneumoniae CAP and bacteremia admitted to
wards or ICUs, initial dual therapy with a macrolide was
associated with better hospital survival compared to a
β-lactam alone. Again, these studies had a different
case-mix, as only 21.1% of our patients had S. pneumo-
niae infection and only 12.7% had bacteremia. Two
studies found no difference between one and two initialantibiotics in patients with severe CAP [13,14]. One was
a post hoc analysis of data from two clinical trials of pa-
tients with severe pneumococcal sepsis and used ICU
survival as the primary outcome, [13] whereas the other
was a randomized trial comparing lefloxacin alone to
ofloxacin plus cefotaxime in patients with severe CAP
but with no shock and used clinical efficacy as the pri-
mary outcome [14]. Thus, neither study is closely simi-
lar to ours. A review article published in 2011 [7]
showed that many studies supporting initial dual ther-
apy in the most severe CAP requiring hospital admis-
sion were often retrospective, used a broad range of
antibiotic regimens with some leading to conflicting re-
sults. As a result, the applicability of their results to
everyday ICU practice can be challenged. In vitro re-
sistance to macrolides has been associated with a higher
clinical failure rate [33]. Despite consistent reports of
increasing resistance to many antibiotics [33,34], treat-
ment failure remains extremely rare in patients with
CAP. That β-lactams are not effective against L. pneu-
mophila may seem to support dual therapy. However, L.
pneumophila infection is rare and routinely sought by
cultures or urine antigen testing (for type 1), with spe-
cific treatment being started at the slightest doubt, as
this strategy has been shown to improve survival [35].
The main rationale for dual therapy is that the broader
spectrum thus obtained covers atypical pathogens (other
than Legionella pneumophila). However, only low-level
evidence is available to support this rationale [19], as
most studies were retrospective and had limited statis-
tical power. The role for atypical pathogens in CAP has
been extensively reviewed [5-7,17,18]. The absence of
benefits from dual therapy on survival in our study may
be partly due to the low frequency of atypical pathogens.
A 2012 Cochrane review of randomized controlled trials
in patients admitted to wards or ICUs for CAP found no
benefit of atypical-pathogen coverage on clinical efficacy
(the primary outcome) or survival, even in the subgroup
of patients with atypical bacteria [36].
Another theoretical reason for using dual therapy is the
possibility of improved effectiveness in patients with CAP
due to resistant bacteria. We excluded patients with
COPD and those admitted from long-term healthcare fa-
cilities, in whom repeated exposure to antibiotics increases
the risk of bacterial resistance. The resulting low propor-
tion of patients with initial bacterial resistance may have
contributed to the absence of an effect of dual therapy on
survival in our study.
Dual therapy might be expected to improve outcomes
of patients with the most severe forms of CAP. Dual
therapy was associated with better 28-day survival in pa-
tients with CAP and septic shock [3] and with better
ICU survival in patients with severe CAP including
75.7% with septic shock [8]. In a retrospective study,
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provided better 14-day and 30-day survival than did a
fluoroquinolone alone in patients admitted for severe
CAP [37]. In our study confined to ICU patients, dual
therapy was not better than monotherapy, even when
the second antibiotic was a macrolide. Patients with
severe CAP usually undergo comprehensive investiga-
tions on an emergency basis, and their antibiotics are
very quickly adapted to the microscopic smear results
than to the susceptibility test results. This approach
may decrease the impact of initial empirical dual anti-
biotic therapy.
Overuse of antibiotics, particularly fluoroquinolones
[38,39], might increase the risks of MDR bacteria selec-
tion and nosocomial pneumonia, although convincing
clinical data to support these possibilities is lacking [40].
Secondary identification of MDR bacteria and nosocomial
pneumonia occurred in similar proportions of patients in
the monotherapy and dual therapy groups in our study.
This finding should not be construed as evidence that un-
necessary antibiotic use is harmless. Widespread antibiotic
overuse does select MDR bacteria. Furthermore, both
macrolides and fluoroquinolones can cause arrhythmias
by prolonging the QT interval [41].
The strengths of our study are the large sample size,
prospective data collection, patient identification based
on clinical variables as opposed to codes [20], high qual-
ity of the database, and careful adjustment for confound-
ing variables. Furthermore, to avoid including patients
with healthcare-associated infections, which require spe-
cific treatment approaches, we excluded patients with
immunodeficiencies, COPD or chronic dialysis as well as
patients admitted from long-term healthcare facilities.
The main limitation of our study is the observational de-
sign without random allocation of the initial antibiotic
regimen. Randomized studies specifically evaluating β-
lactam therapy alone or with a macrolide or fluoro-
quinolone would probably require very large sample
sizes. Also, we had no information on antibiotic use in
the six months preceding the CAP episode or on recent
and/or repeated contact of the patients with healthcare
professionals. This last factor may explain the high pro-
portion of patients with gram-negative bacilli in our
study. However, the possibility that patients with
healthcare-associated pneumonia may be at increased
risk of death because of their distinctive bacteriological
features (including increased resistance) was challenged
recently [28]. The higher mortality in these patients may
be related instead to other factors, including functional
impairments, malnutrition and a more restrictive ICU-
admission policy. After careful adjustment for these fac-
tors, mortality was not significantly increased. Thus,
there may be no sound rationale for modifying current
guidelines for this particular population [28].Conclusions
In conclusion, initial adequate therapy was associated with
better 60-day survival in our patients with CAP requiring
ICU admission and without COPD or immunodeficiency.
Dual therapy (β-lactam plus macrolide or fluoroquino-
lone), compared to monotherapy (β-lactam alone), was as-
sociated with adequacy of initial antibiotic therapy but did
not improve 60-day survival. Dual therapy did not in-
crease the risks of nosocomial pneumonia or secondary
bacterial multidrug resistance.Key messages
 Initial adequate therapy was associated with better
60-day survival in ICU patients admitted for
community-acquired pneumonia.
 Dual therapy with a β-lactam plus a macrolide or
fluoroquinolone, although usually recommended as
better than β-lactam monotherapy in severe
community-acquired pneumonia, improved the
adequacy of initial antibiotic therapy but did not
improve 60-day survival.
 Dual therapy with a β-lactam plus a macrolide or
fluoroquinolone did not increase the risk of nosocomial
pneumonia or multidrug-resistant bacteria.
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